FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases

Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients
with eosinophil-driven diseases.


GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved
Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with
Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary
cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for
patients with this eosinophil-driven disease in the US.

Dr Hal Barron, Chief Scientific Officer, and President R&D, GSK, said: “HES is a complex, life-threatening
a condition that impacts nearly 5,000 patients in the US. Today’s approval gives these patients access to a
biologic treatment for the first time and demonstrates our commitment to maximizing Nucala’s impact on
eosinophil-driven diseases.”

The FDA approval follows a priority review of data from a clinical development program that included
positive results from a pivotal phase 3 study, recently published in the Journal of Allergy and Clinical
Immunology. The study showed 50 percent fewer patients experienced a HES flare (worsening of
symptoms or eosinophil threshold requiring an escalation in therapy) when treated with Nucala,
compared to placebo, when added to standard of care treatment over the 32-week study period (28% vs
56%; p=0.002).

According to Dr. Gerald Gleich, MD, allergist, immunologist, and a HES expert: “Patients with HES often
suffer from debilitating flares of their disease. Reducing them is an important treatment goal. For the first
time, we now have a biologic treatment option to offer appropriate patients with this complex disease.”
Patients with HES have a persistent and marked overproduction of eosinophils, a type of white blood
cell. Reducing the overproduction of eosinophils to normal levels can help people with eosinophil-driven
diseases such as HES.

Mary Jo Strobel, Executive Director, American Partnership for Eosinophilic Disorders (APFED) added:
“HES can take many years to diagnose and most patients go through a long and frustrating journey that
continues even after the diagnosis is confirmed as treatment roadmaps are often unclear and limited.
APFED welcomes this approval of Nucala for HES as it gives our community hope.”

Nucala is currently used as an add-on maintenance therapy for severe eosinophilic asthma and for the
treatment of eosinophilic granulomatosis with polyangiitis (EGPA), and is being investigated in several
other eosinophil-driven diseases.

Tags : #LatestPharmaNewsSep26 #LatestGskNewsSep26 #eosinophildrivendiseases #treatment #foHypereosinophilicSyndrome #GlaxoSmithKline

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026